Melanoma Insights

Gilliosa Spurrier-Bernard
Melanoma Patients Network Europe and MelanomeFrance
MPNE is a volunteer based network whose activities are funded by balanced support for project and support funding from: Amgen, BMS, Merck MSD, Novartis and Roche. Support never includes editorial rights or influence on MPNE’s program or activities.
Why Melanoma at an HIV Meeting?

Before 2012 Metastatic Melanoma patients lived 6-9 months.

At ACCR2017 the OS with Combination Immunotherapies is 64% - Death to potential Cure in 5 years.

Melanoma has high genetic instability, high heterogeneity and fast evolving tumors that are difficult to treat – similarities with HIV.

The Immunotherapies “supercharge” the body’s own immune system – a scenario that might be useful in other fast-evolving conditions - HIV.

We ALL want schemes that give us Evidence and Access.
The 4 years that made the difference in Melanoma

OS 2yr
15%

Interleukin-2 approved by FDA in 1998

Ipilimumab approved by FDA/EMA (03-2011 / 07-2011)

OS 2yr
45%


OS 2yr
59%

Ipilimumab / Nivolumab approved by FDA/EMA (10/15-03/16)

OS 2yr
64%

T-VEC approved by FDA/EMA (10-2015)

IMMUNOTHERAPIES

TARGETED THERAPIES

DTIC approved by FDA in 1975

Vemurafenib approved by FDA/EMA (08-2011 / 12-2011)

Dabrafenib approved by FDA/EMA (05-2013 / 06-2013)

Trametinib approved by FDA/EMA (05-2013 / 04-2014)

Dabrafenib/Trametinib approved by FDA/EMA (09-2015)

Vemurafenib/ Cobimetinib approved by FDA/EMA (11-2015)
CHALLENGES

• New therapeutic class- we were the first
• Limited dose/effect relationship
• Unpredictable responses (led to irRECIST)
• “Once on immune therapy, always on immune therapy”
• Large benefit in a small proportion of patients but lack of predictive markers
• unfamiliar side effect profiles
• high cost
THE FUTURE

• Biomarkers: predictive for treatment response but also resistance to therapy
• Combination therapies - altering tumor environment,
• Enhancing tumor immunogenicity
• Treatment duration and schedules
• Limiting both clinical as well as financial toxicity
Article 8 Helsinki Declaration
While the primary purpose of medical research is to generate new knowledge, this goal can NEVER take precedence over the rights and interests of individual research subjects.
MELANOMA PATIENTS NETWORK EUROPE

1. patients first
2. solutions, not problems
3. data, not opinions
4. if you don’t do it- no one will

MELANOMEFRANCE